𝔖 Bobbio Scriptorium

✦ LIBER ✦

Gemcitabine cost effective in NSCLC

✍ Scribed by Kenyon, Janet

Book ID: 121645017
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 1997
Weight: 97 KB
Volume: 122
Category: Article
ISSN: 1173-5503
DOI: 10.1007/BF03271833

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine alone or in combination with

Gemcitabine alone or in combination with cisplatin cost effective in NSCLC

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 140 KB

1057 The health economics of lung cancer

1057 The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC

✍ Evans, W.K. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 162 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

A Cost-Effectiveness Analysis of Cisplat

A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

✍ Bryden, P.A.; Kumar, G.; Winfree, K.B.; Boye, M.E.; Taipale, K.; Thompson, R.; B 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS C

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

✍ MJ Nuijten; C Holmberg; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB